Vericel Secures FDA Approval for New State-of-the-Art Advanced Therapy Manufacturing Facility
Summary
Vericel announced that its new state-of-the-art advanced therapy manufacturing facility has received FDA approval. This significant regulatory milestone follows the company's robust financial results for fiscal year 2025, indicating a strategic expansion of operational capabilities. The approval is crucial as it de-risks future production, ensures regulatory compliance, and enables Vericel to begin commercial MACI production at the new site in Q2 2026. This expanded capacity is vital for supporting the growth of its advanced therapy portfolio and meeting anticipated demand. Traders should monitor the successful ramp-up of production at the new facility and its impact on future revenue guidance.
At the time of this announcement, VCEL was trading at $34.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.7B. The 52-week trading range was $29.24 to $52.06. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.